The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
15-Oct-13
$64 million
Target:
Detergents & Intermediates Business Unit of Clariant International Ltd
Acquiror:
International Chemical Investors Group
Advised Clariant International Ltd, the Swiss specialty chemicals company, on the sale of its Detergents & Intermediates Business Unit to International Chemical Investors Group, a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses
20-May-13
$8.5 billion
Target:
Warner Chilcott, plc
Acquiror:
Actavis, Inc.
Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc
07-Dec-12
$43 million
Target:
Champion Flour Limited
Acquiror:
Nisshin Seifun Group Inc.
Advised Goodman Fielder, a leading Australian listed food company, on the sale of its New Zealand flour milling business, Champion Flour, to Nisshin Seifun Group Inc.
20-Sep-12
$1.0 billion
Target:
Becker Underwood
Acquiror:
BASF
Advised Norwest Equity Partners on the sale of its portfolio company Becker Underwood, a global leader in the development and commercialization of yield-improving seed-applied biological products for the Agricultural market, to BASF, the world’s largest chemical company
01-Mar-12
$NA
Target:
Minority stake in Stadler Rail
Acquiror:
Peter Spuhler
Advised Capvis, one of the leading buyout firms in Switzerland and one of the main mid-market private equity firms in German-speaking Europe, on the staged exit from of its 20% minority stake in Stadler Rail, by selling to Peter Spuhler, CEO and majority shareholder in Stadler Rail
30-Jun-11
$609 million
Target:
Diabetes-related patent estate and royalty stream of Astellas Pharma subsidiary, Prosidion
Acquiror:
Royalty Pharma
Advised Royalty Pharma, a leading acquiror of biopharmaceutical royalty interests, on the acquisition of the DPP-IV patent estate and associated royalty stream of Astellas Pharma subsidiary, Prosidion
22-Jun-11
$NA
Target:
KemFine Group Oy
Acquiror:
CABB AG
Advised 3i on the disposal of KemFine Group Oy, a leading custom manufacturer of fine chemicals, to CABB AG
08-Jun-11
$1.7 billion
Target:
Citigroup (selected private equity assets)
Acquiror:
AXA Private Equity
Advised AXA Private Equity, a leading European diversified private equity firm, on its acquisition of a $1.7 billion portfolio of limited partnership interests in private equity buyout funds and a portfolio of direct stakes in companies from Citigroup
21-Mar-11
$NA
Target:
Close Brothers Cayman Limited
Acquiror:
Intertrust Group Holdings SA
Advised Close Brothers plc, an independent financial services group, on the sale of its Cayman based offshore business to Intertrust Group Holdings SA
11-Mar-11
$1.0 billion
Target:
Troika Dialog Group Limited
Acquiror:
Sberbank
Advised TD Advisors Limited, a major shareholder of Troika Dialog Group, Russia’s leading investment bank, on the sale of their stake as part of the acquisition of Troika Dialog Group by Sberbank, the largest commercial bank in Russia
01-Mar-11
$128 million
Target:
Tyndall Investments
Acquiror:
Nikko Asset Management
Advised Suncorp, on the sale of its investment management business, Tyndall Investments, in Australia and New Zealand to Nikko Asset Management, a leading Asian mutual funds management company
15-Jan-11
$105 million
Target:
telerob Holding GmbH
Acquiror:
Cobham plc
Advised the shareholders of telerob Holding GmbH, a German-based market leader in the development and manufacture of advanced bomb disposal robots and integrated threat response vehicles, on the sale of the Company to Cobham plc, the UK-based, internationally operating aerospace, defence and security technology group
29-Dec-10
$1.8 billion
Target:
TOWER Australia Group Limited
Acquiror:
The Dai-ichi Life Insurance Company, Limited
Advised TOWER Australia Group Limited, the largest mono-line life insurance company in Australia, in relation to the offer from The Dai-ichi Life Insurance Company, Limited to acquire all of the shares in TOWER that it does not already own by way of a scheme of arrangement
15-Dec-10
$12.9 billion
Target:
Alcon, Inc.
Acquiror:
Novartis AG
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
01-Dec-10
$NA
Target:
Planar Solutions, LLC
Acquiror:
FUJIFILM Corporation
Advised Wacker Chemie AG on the sale of Wacker Chemical Corporation’s 50% equity stake in Planar Solutions LLC, a dedicated CMP slurry manufacturer, to its JV partner, FUJIFILM Corporation
01-Dec-10
$100 million
Target:
Clyde Process Solutions plc
Acquiror:
S-Process Equipment International S.à r.l. (Schenck Process)
Advised S-Process Equipment International S.à r.l. (“Schenck Process”), a global leader in bulk material handling, providing applications incorporating weighing, feeding, screening and automation solutions, on its acquisition of Clyde Process Solutions plc, a global provider of pneumatic conveying and air filtration solutions for process industries
16-Sep-10
$NA
Target:
KemFine UK Ltd
Acquiror:
AURELIUS AG
Advised KemFine Group Oy, a 3i portfolio company, on the sale of its UK-based fine chemicals business, KemFine UK Ltd, to AURELIUS AG
22-Apr-10
$1.9 billion
Target:
Bank of America Corporation
Acquiror:
AXA Private Equity
Advised AXA Private Equity, a leading European diversified private equity firm, on the acquisition of a portfolio of limited partnership interests in private equity funds from Bank of America
09-Feb-10
$672 million
Target:
SAS Group
Acquiror:
Norwegian Government
Advised the Norwegian Government on strategic and financial matters in relation to a refinancing including a conditional capital injection in SAS, the leading airline group in Northern Europe
09-Nov-09
$327 million
Target:
Enzon Pharmaceuticals, Inc.
Acquiror:
Sigma-Tau Pharmaceuticals
Advised Enzon Pharmaceuticals, Inc., a biopharmaceutical company on the sale of its specialty pharmaceutical business to Sigma-Tau, an Italian pharmaceutical company
06-Jul-09
$2.0 billion
Target:
PARIS RE Holdings Ltd.
Acquiror:
PartnerRe Ltd.
Advised PartnerRe Ltd., a leading global reinsurer, providing multi-line reinsurance to insurance companies, on its acquisition of PARIS RE Holdings Ltd., a French-listed, Swiss-based diversified reinsurer
18-May-09
$114 million
Target:
Close Brothers Corporate Finance Holdings Ltd.
Acquiror:
Daiwa Securities SMBC Europe Ltd.
Advised Close Brothers Group plc, an independent financial services group, on the sale of its corporate finance subsidiary to Daiwa Securities SMBC Europe Ltd.
12-Mar-09
$46.9 billion
Target:
Genentech, Inc.
Acquiror:
Roche Holding Ltd.
Advised Roche Holding Ltd., a world-leading provider of healthcare pharmaceuticals and diagnostics, on its acquisition of the outstanding publicly held interest in Genentech, Inc., a leading biotechnology company
12-Oct-08
$6.0 billion
Target:
Hapag-Lloyd AG
Acquiror:
Albert Ballin KG
Advised TUI AG, Europe’s largest tourism company, on its sale of its shipping division Hapag-Lloyd AG, one of the leading global container shipping companies
08-Oct-08
$NA
Target:
MAN Ferrostaal AG
Acquiror:
International Petroleum Investment Company (IPIC)
Advised MAN AG in relation to its 70% sale of MAN Ferrostaal AG, a worldwide supplier of industrial services for the construction of large-scale industrial plants and machine supply, to International Petroleum Investment Company (IPIC)